Neurotrophic Tyrosine Kinase, Receptor, Type 1 (NTRK1) (extracellular domain High affinity nerve growth factor receptor NTRK1 p140-TrkA Trk-A) Antikörper

Antigen: Neurotrophic Tyrosine Kinase, Receptor, Type 1 (NTRK1)

Synonyme: MTC, TRK, TRK1, TRKA, p140-TrkA, DKFZp781I14186, Tkr, trk, TrkA, C80751, trka, Trk, NTRK1, trkA, CTRKA

Epitope: extracellular domain High affinity nerve growth factor receptor NTRK1 p140-TrkA Trk-A

Klonalität: Polyklonal

Wirt: Kaninchen

Reaktivität: Human

Applikation: Immunhistochemie (IHC), Western Blot (WB)

Produktnummer: ABIN351062

Produktbeschreibung

Weitere Bezeichnung: TrkA (High affinity nerve growth factor receptor, NTRK1, p140-TrkA, Trk-A) (extracellular domain)

Swiss-Prot: P04629

Immunogen: A synthetic peptide from the extracellular domain of human TrkA (High affinity nerve growth factor receptor, NTRK1, p140-TrkA, Trk-A) conjugated to an immunogenic carrier protein was used as the immunogen.

Format: Lyophilized

Beschreibung: FUNCTION: Required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. Has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. Activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. SUBUNIT: Exists in a dynamic equilibrium between monomeric (low affinity) and dimeric (high affinity) structures. Binds SH2B2. Interacts with SQSTM1 which bridges NTRK1 to NGFR. Interacts with NGFR and ARMS. Can form a ternary complex with NGFR and ARMS and this complex is affected by the expression levels of ARMS. An increase in ARMS expression leads to a decreased association of NGFR and NTRK1. SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane protein. Note: Endocytosed to the endosomes upon treatment of cells with NGF. TISSUE SPECIFICITY: Isoform Trka-II is primarily expressed in neuronal cells; isoform Trka-I is found in non-neuronal tissues. Also known as: High affinity nerve growth factor receptor, NTRK1, p140-TrkA, Trk-A, Neurotrophic tyrosine kinase receptor type 1, Slow nerve growth factor receptor.

Spezifität: Appears to be specific for TrkA.

Anwendungen

Applikationshinweise: IHC, WB. A dilution of 1 : 300 to 1 : 3000 is recommended. The optimal dilution should be determined by the end user.

Reinheit: whole serum

Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Klein, Jing, Nanduri et al.: "The trk proto-oncogene encodes a receptor for nerve growth factor." in: Cell, Vol. 65, Issue 1, pp. 189-97, 1991 (PubMed).

Hempstead, Martin-Zanca, Kaplan et al.: "High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor." in: Nature, Vol. 350, Issue 6320, pp. 678-83, 1991 (PubMed).

Martin-Zanca, Hughes, Barbacid: "A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences." in: Nature, Vol. 319, Issue 6056, pp. 743-8, 1986 (PubMed).

Martin-Zanca, Oskam, Mitra et al.: "Molecular and biochemical characterization of the human trk proto-oncogene." in: Molecular and cellular biology, Vol. 9, Issue 1, pp. 24-33, 1989 (PubMed).

Loeb, Stephens, Copeland et al.: "A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth." in: The Journal of biological chemistry, Vol. 269, Issue 12, pp. 8901-10, 1994 (PubMed).

Shelton, Sutherland, Gripp et al.: "Human trks: molecular cloning, tissue distribution, and expression of extracellular domain immunoadhesins." in: The Journal of neuroscience : the official journal of the Society for Neuroscience, Vol. 15, Issue 1 Pt 2, pp. 477-91, 1995 (PubMed).

Stephens, Loeb, Copeland et al.: "Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses." in: Neuron, Vol. 12, Issue 3, pp. 691-705, 1994 (PubMed).

Indo, Mardy, Tsuruta et al.: "Structure and organization of the human TRKA gene encoding a high affinity receptor for nerve growth factor." in: The Japanese journal of human genetics, Vol. 42, Issue 2, pp. 343-51, 1997 (PubMed).

Fujimoto, Kitazawa, Maeda et al.: "Methylation adjacent to negatively regulating AP-1 site reactivates TrkA gene expression during cancer progression." in: Oncogene, Vol. 24, Issue 32, pp. 5108-18, 2005 (PubMed).

Gregory, Barlow, McLay et al.: "The DNA sequence and biological annotation of human chromosome 1." in: Nature, Vol. 441, Issue 7091, pp. 315-21, 2006 (PubMed).